
Pro-Dex (PDEX) Stock Forecast & Price Target
Pro-Dex (PDEX) Analyst Ratings
Bulls say
Pro-Dex is benefiting from sustained demand for specialized medical device manufacturing, with fiscal Q4 2026 revenue up 17% year over year to $20.4 million and EPS of $0.86 versus $0.67 expected, reflecting strong new product contribution and operating leverage. Its gross margin improvement to 35% from 20% a year earlier, plus a long record of double-digit annual revenue growth and management’s continued success winning new contracts, supports confidence in durable fundamental momentum. The February 2026 acquisition of Advanced Precision Machining should deepen manufacturing capability, add aerospace and defense exposure, and diversify a customer base that remains concentrated, while the balance sheet of $9 million in cash and $18 million in debt appears manageable.
Bears say
Pro-Dex is exposed to several fundamental headwinds that justify a negative outlook, including volatile demand for technology, weak investor sentiment toward technology stocks, and shifting consumer sentiment that can pressure growth in technology manufacturing. Its business is also vulnerable to intense competition and changing macroeconomic factors, both of which can compress margins and disrupt demand for its medical-device and industrial offerings. Given that the company relies heavily on powered surgical instruments for OEM customers, any slowdown in industry growth or deterioration in broader market conditions could meaningfully weigh on results.
This aggregate rating is based on analysts' research of Pro-Dex and is not a guaranteed prediction by Public.com or investment advice.
Pro-Dex (PDEX) Analyst Forecast & Price Prediction
Start investing in Pro-Dex (PDEX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Pro-Dex (PDEX) Forecast
Pro-Dex (PDEX) Analyst Forecast & Price Prediction
Start investing in Pro-Dex (PDEX)
Order type
Buy in
Order amount
Est. shares
0 shares